ARTBIO Strengthens Leadership with Four New Board Members and Advisory Role for Co-Founder

ARTBIO Strengthens Leadership with New Board Appointments

On August 7, 2025, ARTBIO, Inc., a clinical-stage radiopharmaceutical company, announced the appointment of four new members to its Board of Directors. This strategic movement aims to advance the company’s efforts in developing innovative 212Pb alpha radioligand therapies (ARTs). The new board members bring a wealth of experience from various sectors, adding significant value to ARTBIO's mission to revolutionize cancer treatment.

New Board Members

1. Maha Katabi, Ph.D., CFA
Dr. Katabi is a General Partner at Sofinnova Investments and brings over twenty years of experience managing public and private biotech companies. With a focus on investment maximization, her expertise in pharmacology and investment will be crucial for ARTBIO as it navigates the complexities of the biotech sector.

2. Robert Mittendorff, M.D., MBA
Currently a General Partner and Head of Healthcare at B Capital Group, Dr. Mittendorff has a rich background as both a physician and an executive in public companies. His dual expertise will support ARTBIO's expansion strategies, particularly with his medical and business insights.

3. Julie O'Neill, MBA
An Independent Director with a robust background in healthcare, Mrs. O'Neill has held senior roles in prominent companies like Alexion Pharmaceuticals and Gilead Sciences. Her leadership experience in operations is instrumental for ARTBIO as it seeks to refine its development processes and operational effectiveness.

4. Gabe Gelman
As the Head of Capital Solutions at Baker Bros. Advisors LP, Mr. Gelman brings 25 years of experience from Goldman Sachs where he led crucial biotechnology financings. His financial acumen will play an important role in shaping ARTBIO's investment strategies.

Transition of Co-Founder to Advisory Role

In addition to the new directors, ARTBIO’s co-founder, Dr. Roy Larsen, Ph.D., is transitioning from his position on the Board of Directors to a role within ARTBIO's newly formed Technical Advisory Board. Dr. Larsen's legacy in radiopharmaceuticals is noteworthy, having pioneered significant advancements in cancer treatment methodologies. His ongoing collaboration with ARTBIO is seen as an invaluable asset.

Ted W. Love, M.D., Chairman of the Board, emphasized the importance of these appointments following ARTBIO's recent Series B funding round. He stated, “These appointments will enable ARTBIO to rapidly advance multiple programs designed to have the highest patient impact.” The insights and expertise of the newly appointed members are expected to drive the company’s strategic growth forward.

The Future of ARTBIO

ARTBIO is committed to redefining cancer care with its innovative approach to alpha radioligand therapies. Their unique technology isolates the optimal alpha-precursor isotope (Pb212) and targets tumor-specific characteristics, optimizing both efficacy and safety. The pipeline includes lead program AB001, currently in trials for metastatic castration-resistant prostate cancer, showcasing ARTBIO's determination to bring cutting-edge therapies to patients.

The foundation of ARTBIO is rooted in nearly a century of pioneering work conducted at the University of Oslo and Norway’s Radium Hospital. As it continues to grow and innovate, the company's proactive approach in strengthening its leadership team indicates its commitment to transforming cancer therapy and achieving significant milestones in patient care.

For more information, visit ARTBIO's official website and stay updated by following them on LinkedIn.